Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Test Cleared by FDA as Companion Dx for CLL Drug

NEW YORK (GenomeWeb News) – Abbott announced today that the US Food and Drug Administration has granted premarket approved for the company's Vysis CLL FISH Probe Kit as a companion diagnostic for AbbVie and Genentech's newly approved chronic lymphocytic leukemia (CLL) drug Venclexta (venetoclax).

Venclexta, a BCL-2 inhibitor, received FDA clearance this week for the treatment of CLL patients with a 17p deletion — which is associated with the loss of the TP53 tumor suppressor gene — and who have failed at least one other therapy. The Vysis test is designed to detect genetic abnormalities in lymphocytes including TP53 deletion, and was approved for CLL prognosis in 2011.

According to Abbott, about 5 percent of CLL patients have a TP53 deletion at diagnosis, but the prevelance of TP53 deletion is estimated to be as high as 50 percent for those with relapsed or refractory disease.

Using Abbott's test, physicians can now identify whether patients exhibit TP53 deletion in order to determine whether they would benefit from Venclexta.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.